Biology Studies of Hematologic Cancers

NCT00923442 | Enrolling By Invitation

• 2 other identifiers: 04010204-C-0102
• Study Type: observational
• Target: 550
• Locations: 1 country
• Sites: 1

Brief Summary

This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better understanding of cancer biology and to the development of new treatments. Planned studies include:

• Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells
• Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells
• Development of sensitive methods to detect small amounts of cancer that remain after treatment
• Search for new cancer proteins that might serve as targets for treatment
• Investigation of methods to develop cancer vaccines. Patients from \>= 1 to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study. Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)

Conditions

Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome (MDS)

Keywords

Acute Lymphoblastic Leukemia; Acute Lymphocytic Leukemia; Pediatric Blood Disorders; Hodgkins and non-Hodgkins lymphoma; MDS; Natural History

Outcome Measures

Primary Outcomes (1)

• Tissue acquisition for lab investigations

  The examination of biologic assays relevant to the investigation of hematologic malignancies

  1 Month

Study Arms (1)

1

patients (from \>/= 1 to 75 years old) diagnosed with any hematologic malignancy or pre-malignant condition

Eligibility Criteria

• Age: 1 Year - 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Tumor tissue of patients whose ages range from birth to 75 years old diagnosed with any hematologic malignancy or pre-malignant blood disorder

You may qualify if:

• Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:
• Acute Lymphocytic Leukemia (ALL)
• Acute Myelogenous Leukemia (AML)
• Myelodysplastic Syndrome (MDS)
• Chronic Myelogenous Leukemia (CML)
• Juvenile Myelomonocytic Leukemia (JMML, J-CML)
• Non-Hodgkin's Lymphoma (NHL)
• Hodgkin's Disease
• Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.
• Age: \>= 1 years.
• Prior therapy: no restrictions
• Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.

You may not qualify if:

• None

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Location

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Hodgkin Disease

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Bone Marrow Diseases; Lymphoma; Leukemia, Myeloid

Study Officials

• John W Glod, M.D.

  National Cancer Institute (NCI)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 17, 2009
• First Posted: June 18, 2009
• Study Start: February 24, 2004
• Last Updated: April 27, 2026

Record last verified: 2026-04-17

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: Clinical data available during the study and indefinitely.
• Access Criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

Locations

US (1)